Company profile: Vividion Therapeutics
1.1 - Company Overview
Company description
- Provider of a proteome-wide chemoproteomic platform for drug and target discovery and small-molecule therapeutics in oncology and immunology, including programs for NRF2 inhibition in squamous lung, head, neck and esophageal cancers; NRF2 activation for inflammation-induced tissue injury; STAT3 targeting (incl. oral investigational VVD-130850 for advanced solid and hematologic tumors); and Werner helicase targeting for microsatellite instability cancers.
Products and services
- Chemoproteomic Platform: Architects a proteome-wide technology identifying functional pockets on human proteins and engineers small-molecule therapeutics for oncology and immunology by accessing proteins expressed in human cells
- VVD-130850: An investigational oral small-molecule inhibitor of STAT3 for treating advanced solid and hematologic tumors, suited for oncology indications
- NRF2 Oncology Program: A mechanism-specific program that inhibits NRF2 to treat cancers, particularly squamous cancers of the lung, head, neck, and esophagus
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vividion Therapeutics
rMark Bio
HQ: United States
Website
- Description: Provider of intelligence solutions to the life science industry through Fabric, a patented intelligence platform that unites real-time pharmaceutical business objectives with the activities of academic and clinical researchers to deliver next best decisions, remove inefficiencies, and increase ROI in thought leader engagements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full rMark Bio company profile →
FlowJo
HQ: United States
Website
- Description: Provider of life sciences software for flow cytometry and single-cell analysis, offering FlowJo for viewing and analyzing flow cytometric data (sample management, gating, statistics, graphical layouts), BD Research Cloud for secure cloud storage, sharing and collaboration with integration to analysis software, and SeqGeq for single-cell RNA sequencing (scRNA-seq) data analysis and visualization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FlowJo company profile →
TraceLink
HQ: United States
Website
- Description: Provider of a SaaS network creation platform that connects people, companies, systems, and processes to build integrated business ecosystems with multienterprise applications, enabling digitalization, customer-centric agility and resiliency across end-to-end supply networks and leveraging the collective intelligence of entire industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TraceLink company profile →
Abbott
HQ: United States
Website
- Description: Provider of lab data management solutions, including LIMS, SDMS, and ELN, that integrate with current systems and can be rapidly configured to fit unique workflows without adding complexity or interrupting daily operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abbott company profile →
BioBright
HQ: United States
Website
- Description: Provider of scientific lab data automation software that automates the flow of data from laboratory instruments to secure cloud databases. Solutions include the Dotmatics Luma R&D Data Management Platform and Luma Lab Connect to ingest, centralize, standardize, and model data from in-house and external sources in any file format, enable real-time synchronization, easy access and analysis for non-technical users, and low-code app building.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioBright company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vividion Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vividion Therapeutics
2.2 - Growth funds investing in similar companies to Vividion Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vividion Therapeutics
4.2 - Public trading comparable groups for Vividion Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →